Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-lable, Single Arm, Single Center, Phase 2 Study of PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell

NCT03701022 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03701022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03701022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-lable, Single Arm, Single Center, Phase 2 Study of PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
October 20, 2018
Completion date
June 30, 2021
Enrollment
61 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nk/t-cell lymphoma